
Europe Anti-Obesity Drugs Market Report and Forecast 2024-2032
Description
Europe Anti-Obesity Drugs Market Report and Forecast 2024-2032
Europe Anti-Obesity Drugs Market Report and Forecast 2024-2032
Europe Anti-Obesity Drugs Market Outlook
The anti-obesity drugs market size was valued at USD 2.5 billion in 2023, with Europe holding a significant market share. It is driven by the rising prevalence of obesity. The global market is expected to grow at a CAGR of 10.70% during the forecast period of 2024-2032, with the values likely to attain USD 6.3 billion by 2032.
Key Takeaways
- In Europe, the United Kingdom has one of the highest obesity rates, with 27.8% of the population falling under the obese category. The rising prevalence of obesity is expected to drive market demand.
- One of the major Europe anti-obesity drugs market trends is the increased investment in obesity drug production to reduce shortages and improve accessibility for weight loss medications. In November 2023, Novo Nordisk A/S invested USD 2.3 billion in a French facility to fuel the production of its anti-obesity drugs, including Wegovy and Ozempic.
- Expansion in production facilities is poised to address manufacturing needs and stimulate innovation in the anti-obesity drugs in the region. In November 2023, Eli Lilly and Company invested USD 2.5 billion to build a manufacturing plant in Germany to boost the production capacity of its diabetes and obesity drugs including Mounjaro and Trulicity.
The market is witnessing steady growth driven by the increasing prevalence of obesity in the region. Various factors such as unhealthy eating habits, sedentary lifestyles, and certain genetic predispositions, among others, are resulting in the sharp growth of the bariatric population. In Europe, the United Kingdom has one of the highest obesity rates, with 27.8% of the population falling under the obese category. With the rising obesity prevalence, the Europe anti-obesity drugs market demand is likely to witness a surge owing to the efficacy of these medications in managing weight and reducing associated health risks.
One of the major market trends is the increased investment in anti-obesity drug production by the leading market players to meet the growing demand for weight management medications. In November 2023, the global healthcare company Novo Nordisk A/S invested USD 2.3 billion in a French facility to fuel the production of its anti-obesity drugs. The funding will amplify the manufacturing capacity for Novo’s popular weight loss drugs, Wegovy and Ozempic, along with other obesity treatments under development. Such substantial investments are expected to reduce shortages and improve accessibility for weight loss medications, thereby propelling the Europe anti-obesity drugs market growth in the forecast period.
In November 2023, a similar investment initiative was taken by Eli Lilly and Company, intended to address the soaring demand for anti-obesity drugs in Europe. The company revealed its plan to invest USD 2.5 billion to build a manufacturing plant in Germany to boost the production capacity of its diabetes and obesity drugs such as Mounjaro and Trulicity. The expansion of such production facilities in the region is poised to accommodate manufacturing needs and stimulate innovation in the obesity treatment segment, thereby fuelling market share.
Europe Anti-Obesity Drugs Market Segmentation
Market Breakup by Drugs
- Semaglutide
- Phentermine/Topiramate
- Naltrexone/Bupropion
- Liraglutide
- Gelesis 100
- Orlistat
- Phentermine
- Methamphetamine
- Tirzepatide
- Amphetamine
- GLP-1 Receptor Agonist
- Lipase Inhibitor
- Centrally Acting Drugs
- Peripherally Acting Drugs
- Oral
- Subcutaneous
- Prescription Drugs
- Over The Counter Drugs
- Hospital Pharmacies
- Drug Store and Retail Pharmacies
- Online Pharmacies
- United Kingdom
- Germany
- France
- Italy
- Others
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- VIVUS Inc
- Pfizer, Inc.
- Novo Nordisk
- Bayer AG
- F. Hoffmann-La Roche
- Glaxosmithkline
- Arena Pharmaceuticals
- Eisai Co. Ltd
- Takeda Pharmaceutical Company
- Nalpropion Pharmaceuticals Inc
FAQs
- What is the Europe anti-obesity drugs market forecast outlook for 2024-2032?
- What are the major factors aiding the Europe anti-obesity drugs market demand?
- What are the major Europe anti-obesity drugs market trends?
- What is the market segmentation based on the drugs?
- What are the various drug classes available in the market?
- What is the market breakup by mechanism of action?
- What is the market segmentation based on the route of administration?
- What is the market segmentation based on the prescription type?
- What are the major distribution channels of anti-obesity drugs?
- What is the market segmentation by countries?
- Who are the key players involved in the Europe anti-obesity drugs market?
Meta description
The Europe anti-obesity drugs market is poised for growth, driven by the expansion of the global market, which was valued at USD 2.5 billion in 2023 and is projected to grow at a CAGR of 10.70% during the forecast period of 2024-2032.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
140 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Europe Anti-Obesity Drugs Market Overview
- 3.1 Europe Anti-Obesity Drugs Market Historical Value (2017-2023)
- 3.2 Europe Anti-Obesity Drugs Market Forecast Value (2024-2032)
- 4 Europe Anti-Obesity Drugs Market Landscape*
- 4.1 Europe Anti-Obesity Drugs Market: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Europe Anti-Obesity Drugs Market: Product Landscape
- 4.2.1 Analysis by Product
- 4.2.2 Analysis by Material
- 4.2.3 Analysis by Type
- 5 Europe Anti-Obesity Drugs Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Analysis
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Europe Anti-Obesity Drugs Market Segmentation (2017-2032)
- 6.1 Europe Anti-Obesity Drugs Market (2017-2032) by Drugs
- 6.1.1 Market Overview
- 6.1.2 Semaglutide
- 6.1.3 Phentermine/Topiramate
- 6.1.4 Naltrexone/Bupropion
- 6.1.5 Liraglutide
- 6.1.6 Gelesis 100
- 6.1.7 Orlistat
- 6.1.8 Phentermine
- 6.1.9 Methamphetamine
- 6.1.10 Tirzepatide
- 6.2 Europe Anti-Obesity Drugs Market (2017-2032) by Drug Class
- 6.2.1 Market Overview
- 6.2.2 Amphetamine
- 6.2.3 GLP-1 receptor agonist
- 6.2.4 Lipase Inhibitor
- 6.3 Europe Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
- 6.3.1 Market Overview
- 6.3.2 Centrally Acting Drugs
- 6.3.3 Peripherally Acting Drugs
- 6.4 Europe Anti-Obesity Drugs Market (2017-2032) by Route of Administration
- 6.4.1 Market Overview
- 6.4.2 Oral
- 6.4.3 Subcutaneous
- 6.5 Europe Anti-Obesity Drugs Market (2017-2032) by Prescription Type
- 6.5.1 Market Overview
- 6.5.2 Prescription Drugs
- 6.5.3 Over The Counter Drugs
- 6.6 Europe Anti-Obesity Drugs Market (2017-2032) by Distribution Channel
- 6.6.1 Market Overview
- 6.6.2 Hospital Pharmacies
- 6.6.3 Drug Store & Retail Pharmacies
- 6.6.4 Online Pharmacies
- 6.7 Europe Anti-Obesity Drugs Market (2017-2032) by Countries
- 6.7.1 Market Overview
- 6.7.2 United Kingdom
- 6.7.3 Germany
- 6.7.4 France
- 6.7.5 Italy
- 6.7.6 Others
- 7 United Kingdom Anti-Obesity Drugs Market (2017-2032)
- 7.1 United Kingdom Anti-Obesity Drugs Market (2017-2032) By Drugs
- 7.1.1 Market Overview
- 7.1.2 Semaglutide
- 7.1.3 Phentermine/Topiramate
- 7.1.4 Naltrexone/Bupropion
- 7.1.5 Liraglutide
- 7.1.6 Gelesis 100
- 7.1.7 Orlistat
- 7.1.8 Phentermine
- 7.1.9 Methamphetamine
- 7.1.10 Tirzepatide
- 7.2 United Kingdom Anti-Obesity Drugs Market (2017-2032) by Drug Class
- 7.2.1 Market Overview
- 7.2.2 Market Overview
- 7.2.3 Amphetamine
- 7.2.4 GLP-1 receptor agonist
- 7.2.5 Lipase Inhibitor
- 7.3 United Kingdom Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
- 7.3.1 Market Overview
- 7.3.2 Centrally Acting Drugs
- 7.3.3 Peripherally Acting Drugs
- 7.4 United Kingdom Anti-Obesity Drugs Market (2017-2032) by Route of Administration
- 7.4.1 Market Overview
- 7.4.2 Oral
- 7.4.3 Subcutaneous
- 7.5 United Kingdom Anti-Obesity Drugs Market (2017-2032) by Prescription Type
- 7.5.1 Market Overview
- 7.5.2 Prescription Drugs
- 7.5.3 Over The Counter Drugs
- 7.6 United Kingdom Anti-Obesity Drugs Market (2017-2032) By Distribution Channel
- 7.6.1 Market Overview
- 7.6.2 Hospital Pharmacies
- 7.6.3 Drug Store & Retail Pharmacies
- 7.6.4 Online Pharmacies
- 8 Germany Anti-Obesity Drugs Market (2017-2032)
- 8.1 Germany Anti-Obesity Drugs Market (2017-2032) By Drugs
- 8.1.1 Market Overview
- 8.1.2 Semaglutide
- 8.1.3 Phentermine/Topiramate
- 8.1.4 Naltrexone/Bupropion
- 8.1.5 Liraglutide
- 8.1.6 Gelesis 100
- 8.1.7 Orlistat
- 8.1.8 Phentermine
- 8.1.9 Methamphetamine
- 8.1.10 Tirzepatide
- 8.2 Germany Anti-Obesity Drugs Market (2017-2032) by Drug Class
- 8.2.1 Market Overview
- 8.2.2 Market Overview
- 8.2.3 Amphetamine
- 8.2.4 GLP-1 receptor agonist
- 8.2.5 Lipase Inhibitor
- 8.3 Germany Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
- 8.3.1 Market Overview
- 8.3.2 Centrally Acting Drugs
- 8.3.3 Peripherally Acting Drugs
- 8.4 Germany Anti-Obesity Drugs Market (2017-2032) by Route of Administration
- 8.4.1 Market Overview
- 8.4.2 Oral
- 8.4.3 Subcutaneous
- 8.5 Germany Anti-Obesity Drugs Market (2017-2032) by Prescription Type
- 8.5.1 Market Overview
- 8.5.2 Prescription Drugs
- 8.5.3 Over The Counter Drugs
- 8.6 Germany Anti-Obesity Drugs Market (2017-2032) By Distribution Channel
- 8.6.1 Market Overview
- 8.6.2 Hospital Pharmacies
- 8.6.3 Drug Store & Retail Pharmacies
- 8.6.4 Online Pharmacies
- 9 France Anti-Obesity Drugs Market (2017-2032)
- 9.1 France Anti-Obesity Drugs Market (2017-2032) By Drugs
- 9.1.1 Market Overview
- 9.1.2 Semaglutide
- 9.1.3 Phentermine/Topiramate
- 9.1.4 Naltrexone/Bupropion
- 9.1.5 Liraglutide
- 9.1.6 Gelesis 100
- 9.1.7 Orlistat
- 9.1.8 Phentermine
- 9.1.9 Methamphetamine
- 9.1.10 Tirzepatide
- 9.2 France Anti-Obesity Drugs Market (2017-2032) by Drug Class
- 9.2.1 Market Overview
- 9.2.2 Market Overview
- 9.2.3 Amphetamine
- 9.2.4 GLP-1 receptor agonist
- 9.2.5 Lipase Inhibitor
- 9.3 France Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
- 9.3.1 Market Overview
- 9.3.2 Centrally Acting Drugs
- 9.3.3 Peripherally Acting Drugs
- 9.4 France Anti-Obesity Drugs Market (2017-2032) by Route of Administration
- 9.4.1 Market Overview
- 9.4.2 Oral
- 9.4.3 Subcutaneous
- 9.5 France Anti-Obesity Drugs Market (2017-2032) by Prescription Type
- 9.5.1 Market Overview
- 9.5.2 Prescription Drugs
- 9.5.3 Over The Counter Drugs
- 9.6 France Anti-Obesity Drugs Market (2017-2032) By Distribution Channel
- 9.6.1 Market Overview
- 9.6.2 Hospital Pharmacies
- 9.6.3 Drug Store & Retail Pharmacies
- 9.6.4 Online Pharmacies
- 10 Italy Anti-Obesity Drugs Market (2017-2032)
- 10.1 Italy Anti-Obesity Drugs Market (2017-2032) By Drugs
- 10.1.1 Market Overview
- 10.1.2 Semaglutide
- 10.1.3 Phentermine/Topiramate
- 10.1.4 Naltrexone/Bupropion
- 10.1.5 Liraglutide
- 10.1.6 Gelesis 100
- 10.1.7 Orlistat
- 10.1.8 Phentermine
- 10.1.9 Methamphetamine
- 10.1.10 Tirzepatide
- 10.2 Italy Anti-Obesity Drugs Market (2017-2032) by Drug Class
- 10.2.1 Market Overview
- 10.2.2 Market Overview
- 10.2.3 Amphetamine
- 10.2.4 GLP-1 receptor agonist
- 10.2.5 Lipase Inhibitor
- 10.3 Italy Anti-Obesity Drugs Market (2017-2032) by Mechanism of Action
- 10.3.1 Market Overview
- 10.3.2 Centrally Acting Drugs
- 10.3.3 Peripherally Acting Drugs
- 10.4 Italy Anti-Obesity Drugs Market (2017-2032) by Route of Administration
- 10.4.1 Market Overview
- 10.4.2 Oral
- 10.4.3 Subcutaneous
- 10.5 Italy Anti-Obesity Drugs Market (2017-2032) by Prescription Type
- 10.5.1 Market Overview
- 10.5.2 Prescription Drugs
- 10.5.3 Over The Counter Drugs
- 10.6 Italy Anti-Obesity Drugs Market (2017-2032) By Distribution Channel
- 10.6.1 Market Overview
- 10.6.2 Hospital Pharmacies
- 10.6.3 Drug Store & Retail Pharmacies
- 10.6.4 Online Pharmacies
- 11 Regulatory Framework
- 12 Patent Analysis
- 12.1 Analysis by Type of Patent
- 12.2 Analysis by Publication year
- 12.3 Analysis by Issuing Authority
- 12.4 Analysis by Patent Age
- 12.5 Analysis by CPC Analysis
- 12.6 Analysis by Patent Valuation
- 12.7 Analysis by Key Players
- 13 Funding and Investment Analysis
- 13.1 Analysis by Funding Instances
- 13.2 Analysis by Type of Funding
- 13.3 Analysis by Funding Amount
- 13.4 Analysis by Leading Players
- 13.5 Analysis by Leading Investors
- 13.6 Analysis by Geography
- 14 Partnership and Collaborations Analysis
- 14.1 Analysis by Partnership Instances
- 14.2 Analysis by Type of Partnership
- 14.3 Analysis by Leading Players
- 14.4 Analysis by Geography
- 15 Supplier Landscape
- 15.1 Market Share by Top 5 Companies
- 15.2 VIVUS Inc
- 15.2.1 Financial Analysis
- 15.2.2 Product Portfolio
- 15.2.3 Demographic Reach and Achievements
- 15.2.4 Mergers and Acquisitions
- 15.2.5 Certifications
- 15.3 Pfizer, Inc.
- 15.3.1 Financial Analysis
- 15.3.2 Product Portfolio
- 15.3.3 Demographic Reach and Achievements
- 15.3.4 Mergers and Acquisitions
- 15.3.5 Certifications
- 15.4 Novo Nordisk
- 15.4.1 Financial Analysis
- 15.4.2 Product Portfolio
- 15.4.3 Demographic Reach and Achievements
- 15.4.4 Mergers and Acquisitions
- 15.4.5 Certifications
- 15.5 Bayer AG
- 15.5.1 Financial Analysis
- 15.5.2 Product Portfolio
- 15.5.3 Demographic Reach and Achievements
- 15.5.4 Mergers and Acquisitions
- 15.5.5 Certifications
- 15.6 F Hoffmann-La Roche
- 15.6.1 Financial Analysis
- 15.6.2 Product Portfolio
- 15.6.3 Demographic Reach and Achievements
- 15.6.4 Mergers and Acquisitions
- 15.6.5 Certifications
- 15.7 Glaxosmithkline
- 15.7.1 Financial Analysis
- 15.7.2 Product Portfolio
- 15.7.3 Demographic Reach and Achievements
- 15.7.4 Mergers and Acquisitions
- 15.7.5 Certifications
- 15.8 Arena Pharmaceuticals
- 15.8.1 Financial Analysis
- 15.8.2 Product Portfolio
- 15.8.3 Demographic Reach and Achievements
- 15.8.4 Mergers and Acquisitions
- 15.8.5 Certifications
- 15.9 Eisai Co. Ltd
- 15.9.1 Financial Analysis
- 15.9.2 Product Portfolio
- 15.9.3 Demographic Reach and Achievements
- 15.9.4 Mergers and Acquisitions
- 15.9.5 Certifications
- 15.10 Takeda Pharmaceutical Company
- 15.10.1 Financial Analysis
- 15.10.2 Product Portfolio
- 15.10.3 Demographic Reach and Achievements
- 15.10.4 Mergers and Acquisitions
- 15.10.5 Certifications
- 15.11 Nalpropion Pharmaceuticals Inc
- 15.11.1 Financial Analysis
- 15.11.2 Product Portfolio
- 15.11.3 Demographic Reach and Achievements
- 15.11.4 Mergers and Acquisitions
- 15.11.5 Certifications
- 16 Europe Anti-Obesity Drugs Market – Distribution Model (Additional Insight)
- 16.1 Overview
- 16.2 Potential Distributors
- 16.3 Key Parameters for Distribution Partner Assessment
- 17 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 18 Company Competitiveness Analysis (Additional Insight)
- 18.1 Very Small Companies
- 18.2 Small Companies
- 18.3 Mid-Sized Companies
- 18.4 Large Companies
- 18.5 Very Large Companies
- 19 Payment Methods (Additional Insight)
- 19.1 Government Funded
- 19.2 Private Insurance
- 19.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.